Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?
Open Access
- 14 March 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (6), 1315-1325
- https://doi.org/10.1158/1078-0432.ccr-12-2551
Abstract
The European Pediatric Medicine Regulation was launched in 2007 to provide better medicines for children. Five years later, the number of new anticancer drugs in early development in the pediatric population remains low, and most children with cancer are still largely denied access to innovative drugs in Europe, as compared with the United States. We analyzed individual pediatric investigation plan (PIP) and waiver decisions for oncology drugs and all oncology drugs that have been approved for marketing authorization since 2007 in Europe. Among the 45 approved PIPs, 33% concern leukemias and lymphomas, 29% solid tumors, 13% brain tumors, and 20% a drug for supportive care. No specific PIP exists for life-threatening diseases such as high-risk neuroblastoma, whereas there are several PIPs in extremely rare malignancies in children and adolescents such as gastrointestinal stromal tumor, melanoma, thyroid cancer, and chronic myeloid leukemia. This paradoxical situation is due to approval of a PIP being driven by the adult indication. Twenty-six of 28 authorized new oncology drugs have a potentially relevant mechanism of action for pediatric malignancies, but 50% have been waived because the adult condition does not occur in children. The most striking example is crizotinib. Implementation of the pediatric regulation should no longer be driven by the adult indication but should be guided instead by the biology of pediatric tumors and the mechanism of action of a drug. This change will be achievable through voluntary PIPs submitted by Pharma or revocation of the oncology class waiver list. Clin Cancer Res; 19(6); 1315–25. ©2013 AACR.Keywords
This publication has 15 references indexed in Scilit:
- Targeting ALK in neuroblastoma—preclinical and clinical advancementsNature Reviews Clinical Oncology, 2012
- New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient OutcomeClinical Cancer Research, 2012
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN StudyJournal of Clinical Oncology, 2010
- The role of the ‘innovative therapies for children with cancer’ (ITCC) European consortiumCancer Treatment Reviews, 2010
- Will children with cancer benefit from the new European Paediatric Medicines Regulation?European Journal of Cancer, 2009
- Survival of European children and young adults with cancer diagnosed 1995–2002European Journal of Cancer, 2009
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009